Zhangkenney5093

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, robust microgliosis, neuroinflammation, and neuronal loss. Genome-wide association studies recently highlighted a prominent role for microglia in late-onset AD (LOAD). Specifically, inositol polyphosphate-5-phosphatase (INPP5D), also known as SHIP1, is selectively expressed in brain microglia and has been reported to be associated with LOAD. Although INPP5D is likely a crucial player in AD pathophysiology, its role in disease onset and progression remains unclear. We performed differential gene expression analysis to investigate INPP5D expression in AD and its association with plaque density and microglial markers using transcriptomic (RNA-Seq) data from the Accelerating Medicines Partnership for Alzheimer's Disease (AMP-AD) cohort. We also performed quantitative real-time PCR, immunoblotting, and immunofluorescence assays to assess INPP5D expression in the 5xFAD amyloid mouse model. Differential gene expression analysis found that INPP5D expression was upregulated in LOAD and positively correlated with amyloid plaque density. In addition, in 5xFAD mice, Inpp5d expression increased as the disease progressed, and selectively in plaque-associated microglia. Increased Inpp5d expression levels in 5xFAD mice were abolished entirely by depleting microglia with the colony-stimulating factor receptor-1 antagonist PLX5622. Our findings show that INPP5D expression increases as AD progresses, predominantly in plaque-associated microglia. Importantly, we provide the first evidence that increased INPP5D expression might be a risk factor in AD, highlighting INPP5D as a potential therapeutic target. Moreover, we have shown that the 5xFAD mouse model is appropriate for studying INPP5D in AD.B-type allatostatins (AST-B) are neuropeptides that have important physiological roles in arthropods, they have also been identified in a number of crustacean species. CID44216842 supplier Recent research on neuroendocrine-immune (NEI) regulatory system in invertebrates has exploded, it reveals that the NEI network plays an indispensable role in optimizing the immune response and maintaining homeostasis. Herein, mud crab Scylla paramamosain provides a primitive and ancient model to study crosstalk between the neuroendocrine and immune systems. In this study, qRT-PCR analysis showed that the nervous system was the main production site for Sp-AST-B mRNA in S. paramamosain, while its receptor gene (Sp-AST-BR) mRNA could be detected in all the analyzed tissues including hemocytes. This reveals that AST-B might act as a pleiotropic neuropeptide. In situ hybridization further confirmed that granular cells of hemocyte subpopulations express Sp-AST-BR. Time-course analysis revealed that bacteria-analog LPS or virus-analog Poly (IC) challenge significantly induced Sp-AST-B expression in the thoracic ganglion, and the expression of Sp-AST-BR in hemocytes were also positively changed. Furthermore, mud crabs treated with a synthetic AST-B peptide significantly increased the mRNA levels of AST-BR, nuclear factor-κB (NF-κB) transcription factor (Dorsal and Relish), pro-inflammatory cytokine (IL-16) and immune-effector molecules, and also dramatically enhanced the nitric oxide (NO) production and phagocytic activity in hemocytes. Meanwhile dsRNA-mediated knockdown of Sp-AST-B remarkably suppressed the NO concentrations, phagocytic activity and the expression of immune related genes, resulting in markedly impaired ability of crabs to inhibit bacterial proliferation in vivo. Combined, these data demonstrate that AST-B induced innate immune in the mud crab.

Intracerebral hemorrhage (ICH) is the top lethal and disabling form of stroke. The pathophysiology of ICH is not fully understood yet. Metabolites are indicators and regulators of cellular processes. However, the overall brain metabolic pattern and the temporal alterations after ICH remain unknown.

A total of 40 male rats were randomly assigned to sham group and ICH group. ICH was induced by collagenase Ⅶ. Body weight was assessed. Neurological deficits were evaluated by modified neurological severity score. Then, the perihematomal brain tissues were collected for metabolites detection using high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS). The metabolic profiles were displayed by principal component analysis (PCA), partial least-squares-discriminant analysis (PLS-DA) and cluster analysis. The significant differential metabolites were screened by fold change > 2.0, the false discovery rate (FDR) < 0.05 and Variable Importance of Projection (VIP) > 1. Next, the relevant meile influencing amino acid metabolism, urea cycle and peroxisome in the recovery stage.

Our study mapped the pathological metabolomics profiles of the post-ICH rat brains in the acute and recovery phases. This work will assist in discovering novel therapeutic targets and treatments for ICH.

Our study mapped the pathological metabolomics profiles of the post-ICH rat brains in the acute and recovery phases. This work will assist in discovering novel therapeutic targets and treatments for ICH.We sought to investigate whether RVLM iNOS activity and oxidative profile may participate in the reduction of sympathetic responsiveness in swimming trained normotensive rats. Sedentary (S) and swimming trained (T) Wistar male rats chronically instrumented with an arterial catheter and guide cannula into the RVLM were submitted to continuous pressure and heart rate (HR) recordings and determination of autonomic control (power spectral analysis) before and after unilateral RVLM iNOS inhibition (aminoguanidine, 250 pmol/100 nL). Other S and T rats received local l-glutamate microinjection (5 nmol/100 nL). In separate S and T groups not submitted to brainstem cannulation, fresh bilateral RVLM punchs were collected for iNOS gene expression (qPCR); reduced glutathione and lipid peroxidation quantification (spectrophotometry); iron-reducing antioxidant (FRAP) and 2,2'-azino-bis (3-ethylbenzothiazoline-6-sulphonic acid) radical cation (ABTS˙+) scavenger assays. iNOS gene expression was confirmed in fixed RVLM slices (immunofluorescence).